POPULARITY
103 episodes with Osteosarcoma
18 episodes with Osteosarcoma
11 episodes with Osteosarcoma
10 episodes with Osteosarcoma
6 episodes with Osteosarcoma
4 episodes with Osteosarcoma
4 episodes with Osteosarcoma
7 episodes with Osteosarcoma
2 episodes with Osteosarcoma
Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age. In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation of treatments for osteosarcoma (OS) and other solid tumours. Describing the current treatment landscape for primary and secondary bone cancer, Romness explains the potential of their own – OST-HER2, a bioengineered bacterial immunotherapy based on listeria. You can also listen to episode 184a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
After their 16 year old son Zach passed away from Osteosarcoma in November of 2021, Jon and Jenn Wall wanted to start a non profit focused around some type of Peer Counseling. The found it as they established ZACHS BRIDGE which partners parents who have already lost a child to Pediatric Cancer with parents who are going through their own child's pediatric cancer battle. The parents who have lost a child are there to help counsel the parents who are going through this same type of terrible experience, and trying to help them navigate this path as easily as possible.
A personalized immunotherapy has recently been approved for canine osteosarcoma, a bone cancer diagnosed…
A personalized immunotherapy has recently been approved for canine osteosarcoma, a bone cancer diagnosed in about 10,000 dogs each year. The first step of production involves collecting some of the...
OsteoBites welcomes Yingqi Hua, MD from Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine to discuss his work on molecular subtyping of osteosarcoma, ecDNA, and more.Dr. Hua has been engaged in basic and clinical research of malignant bone tumors for more than 10 years, focusing on the individualized comprehensive treatment of advanced bone tumors, and is committed to transforming research results through clinical research. His research interests include 1. Multi-omics study of osteosarcoma: Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. 2. Epigenetic study of bone tumors: the function of histone mutation and the function of different histone methylation modification. 3. Drug screen: Screening sensitive drugs by patient derived xenograft(PDX) and explore the mechanism of drug action. 4. Clinical trial of advanced stage sarcomas based on precision medicine.
About the Guest(s): Dr. Kristin Hieshetter is the host of Functional Health Radio. With a background in chiropractic care and expertise in functional health and wellness, Dr. Kristin is dedicated to bringing accurate and cutting-edge information to her listeners. She is committed to improving public health through education and is involved in Functional Health University and associated initiatives. Episode Summary: In this insightful episode of Functional Health Radio, Dr. Kristin Hieshetter continues her exploration of fluoride and its controversial role in public health. Following the recent federal law that mandates the removal of fluoride from drinking water due to its harmful effects on children's IQs, Dr. Kristin delves into fluoride's potential links to bone diseases and cancer. She emphasizes the need for advocacy at local government levels to ensure the law is implemented effectively. Dr. Kristin critically examines a wealth of research, offering a balanced view of fluoride's implications on health. The episode is rich with historical and scientific context, exploring studies from as far back as 1977. Dr. Kristin reviews literature on the correlation between fluoride exposure and bone cancer, highlighting the significant debates within the scientific community. She underscores the necessity of questioning existing scientific studies and offers practical advice on minimizing fluoride exposure, emphasizing the vital role of water filtration and careful selection of dental hygiene products. This episode serves as a wake-up call for listeners to become more proactive about the substances they and their families ingest. Key Takeaways: New federal law requires the removal of fluoride from drinking water due to its negative impact on children's IQs. Historical and recent studies suggest potential links between fluoride exposure and increased cancer risks, although findings are inconsistent. There is a critical need to filter drinking water to protect against various contaminants beyond fluoride. The design and execution of many past studies on fluoride exposure are flawed, lacking evaluations of urinary fluoride excretion. Advocacy is crucial for implementing and enforcing the new fluoride regulations by actively engaging with local government authorities. Notable Quotes: "The EPA legal allowable limit if you dose people in their water…we are overdosing fluoride, and it is negatively impacting children's IQs." "Fluoride is an inorganic poison…if you don't put it in the water in trace amounts, it can cause crippling skeletal fluorosis." "Let's think critically…Start to question more. More and more and more. Start to question more." "Drinking water fluoride levels were not associated with cancer according to this study of a whole bunch of kids who had cancer." "Be the change you want to see in the world and keep letting that positive light shine." Resources: For more on fluoride research studies, visit PubMed Information on Functional Health University: Erconia website Previous episodes of the podcast discussing fluoride and other health issues: Functional Health Radio (URL not provided in the text) Functional Health Mastery Group Listen to the full episode to gain a deeper understanding of the complexities surrounding fluoride and public health and ensure you never miss an episode full of cutting-edge insights! Stay tuned for more illuminating discussions on Functional Health Radio.
About the Guest(s): Dr. Kristin Hieshetter is a chiropractor with an extensive background in functional health and integrative medicine. She hosts Functional Health Radio and is known for her innovative approaches using therapies like low-level laser treatment to enhance patient care. Dr. Hieshetter is involved in the Integrative Health Institute, where she educates other healthcare professionals on cutting-edge techniques in functional medicine and neurological treatment. Episode Summary: In this insightful episode of Functional Health Radio, Dr. Kristin Hieshetter shares her experiences with using low-level laser therapy for medical interventions. Having recently encountered a personal family situation, she underscores the potential of these treatments in aiding recovery and fostering faster healing, particularly in the context of her mother's hip surgery. The episode pivots around remarkable treatments Dr. Hieshetter provided using a 7.5 milliwatt low-level laser device, acclaimed for its ability to accelerate healing and reduce infection risks. The discussion further delves into the successful use of low-level laser therapy in a groundbreaking open-heart surgery case involving a 12-year-old boy afflicted with a rare genetic disorder known as BPAN. Dr. Hieshetter shares how the use of this therapy during surgical procedures was facilitated by notable collaboration with renowned cardiac surgeon Dr. Cavarana. This collaboration allowed for the first-ever application of low-level laser therapy in an operating room, evidencing its capacity to safeguard against brain cell death and facilitate extraordinary recovery outcomes. Dr. Hieshetter emphasizes the emerging roles of integrative medicine and the importance of interdisciplinary collaboration in achieving optimal patient health outcomes. Key Takeaways: Low-Level Laser Therapy: This non-invasive treatment helps reduce infection risks, enhance mitochondrial function, and accelerate healing, with successful cases in surgical recoveries. Innovative Surgery Application: Dr. Hieshetter facilitated the first use of low-level laser therapy during a pediatric cardiac surgery, achieving significant positive outcomes by preventing brain cell death. BPAN Genetic Disorder: Highlighted is the impact of this rare condition on brain and tissue function, underscoring the need for advanced integrative treatment options. Interdisciplinary Collaboration: The episode underscores effective cooperation between chiropractors and surgeons, driving medical innovation and enhanced patient care. Advocacy for Integrative Health: Dr. Hieshetter asserts the importance of integrative healthcare solutions, stressing their role in improving the future of patient health management. Notable Quotes: "When you can do something that reduces the risk of infection and speeds healing without any risk or side effect, it's miraculous." "The future of health belongs to the integrators." "This is why my very weak 7.5 milliwatt low-level lasers were able to help my mom." "It's not from heat… Photochemistry became a widely accepted hypothesis to explain the induction of photobiological processes." "We were able to articulate the importance of transcranial low-level laser in brain injury and in TBI and in stroke." Resources: Integrative Health Institute: A professional organization dedicated to teaching functional medicine tools to healthcare providers. Medical University of South Carolina: Location where the groundbreaking surgery took place. Functional Health Mastery Group BPAN Genetic Disorder Information: Insights into the condition discussed within the episode. For a deeper understanding and comprehensive insights into the potential of low-level laser therapy and integrative medicine, tune into the full episode. Functional Health Radio continues to bring you innovative solutions and success stories in the world of functional health. Stay connected for more enlightening content.
In this episode, Ayesha spoke with Paul Romness, MHP, chair and CEO of OS Therapies, a company developing novel immunotherapies for cancers like osteosarcoma and other solid tumors. Paul shares insights into OS Therapies' lead program, the scientific rationale behind the company's innovative immunotherapy approach and how the company is addressing unmet needs in osteosarcoma. Paul has over 25 years of experience in the biopharmaceutical industry, having served in various functions within major companies like Johnson & Johnson, Amgen and Boehringer Ingelheim. He has been directly involved in the launch of nine major products in the industry covering indications from oncology to surgery, HIV, COPD and diabetes. Throughout his professional career and within his community, Paul has focused on and advocated for unmet medical need and getting treatments to patients. Paul has a Bachelor of Science (BSc) in finance from American University and a Masters of Health Policy (MHP) from George Washington University Medical Center. Tune in to learn how OS Therapies is advancing immunotherapies for osteosarcoma and other solid tumors through innovative, precision-driven approaches. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Brian Flesner, DVM, MS, DACVIM (Oncology), discusses the recently opened clinical trial studying an Autologous Cancer Vaccine with Checkpoint Inhibitor for the Treatment of Canine Osteosarcoma.The purpose of this study is to evaluate the safety and efficacy of K9-ACV, an autologous killed tumor cell vaccine combined with a novel checkpoint inhibitor (CD200AR-L), compared to standard-of-care chemotherapy for the treatment of canine appendicular osteosarcoma (OSA). K9-ACV has safely been used in over 1,000 dogs, and the vaccine has been shown to display safety in a previous study (without the addition of the checkpoint inhibitor). By evaluating K9-ACV, this trial aims to advance safer, immune-based treatment options for canine cancer that may offer comparable or superior outcomes to chemotherapy.Find more information about this study:https://studypages.com/s/autologous-cancer-vaccine-with-checkpoint-inhibitor-for-treatment-of-canine-osteosarcoma-565406/Adrienne Wright, adrienne@ardentanimalhealth.com, +1 (859) 619-5893
Send us an inquiry through a text message here!Welcome to another episode of The Veterinary Roundtable! In this episode, the ladies discuss the challenges of treating patients at a higher elevation, a handful of My Pets Wellness clinics closing overnight, keeping antimicrobial resistance in mind when treating patients, and more!Do you have a question, story, or inquiry for The Veterinary Roundtable? Send us a text from the link above, ask us on any social media platform, or email theveterinaryroundtable@gmail.com!Episodes of The Veterinary Roundtable are on all podcast services along with video form on YouTube!Instagram: https://tinyurl.com/2h27xnfuTikTok: https://tinyurl.com/m8f62ameYouTube: https://tinyurl.com/48njfywdTIMESTAMPSIntro 00:00Pits And Peaks 04:34Tails From The Trenches 11:32My Pets Wellness Closes All Vet Clinics Overnight 16:50New Immunotherapy Treatment May Delay Metastasis In Dogs With Osteosarcoma 21:18Case Collections 23:36Listener Loves Intranasal Bordetella 31:10Treating Patients At A Higher Elevation 34:00Keep Antimicrobial Resistance In Mind When Treating Patients 37:44Outro 44:28
Osteosarcoma is a rare and aggressive bone cancer that usually affects children and teenagers. Over the past 40 years, there's been little progress to improve survival rates, with the five-year survival rate stagnant at about 60 to 70 percent for localized disease and 15 to 30 percent for metastatic osteosarcoma. OS Therapies is developing an experimental immunotherapy to treat certain osteosarcomas. We spoke to Paul Romness, president and CEO of OS Therapies, about why osteosarcomas have been difficult to treat, the company's experimental therapy for the condition, and the promising results that have been seen to date.
TJ Utset-Ward, MD, cirujano ortopédico del Nicklaus Children's Hospital, ofrece una descripción general de las opciones quirúrgicas y los avances en el osteosarcoma.El tratamiento del osteosarcoma consiste en una combinación de quimioterapia y cirugía para extirpar el tumor. En la década de 1980, la amputación de extremidades se utilizaba en el 80 % de los casos. Hoy en día, gracias a los avances en las técnicas quirúrgicas, la tecnología y nuestro conocimiento del osteosarcoma, más del 90 % de los casos son susceptibles a una cirugía para preservar la extremidad. Hoy en día, los pacientes y sus familias pueden incluso elegir entre varias opciones, incluyendo reconstrucciones que se adaptan al crecimiento del niño. Analizaremos algunas de estas opciones y cirugías, así como los objetivos y prioridades de la cirugía de osteosarcoma.El Dr. T.J. Utset-Ward es cirujano ortopédico pediátrico especializado en oncología ortopédica pediátrica en el Hospital Infantil Nicklaus. Es cubanoamericano, hispanohablante y nativo de la ciudad de Miami, y se siente honrado de servir a su comunidad como uno de los pocos cirujanos oncológicos ortopédicos del país dedicados exclusivamente al sarcoma pediátrico y adolescente. Obtuvo su título de médico en la Facultad de Medicina de la Universidad de Vanderbilt en Nashville, Tennessee. El Dr. Utset-Ward completó su residencia en cirugía ortopédica en la Facultad de Medicina de la Universidad de Chicago/UChicago en Illinois. Realizó una beca de investigación en oncología musculoesquelética en la Universidad Estatal de Ohio en Columbus, Ohio, y posteriormente amplió su formación con una beca de investigación en oncología ortopédica pediátrica en el Hospital Infantil Nationwide. Sus intereses clínicos y de investigación incluyen sarcomas óseos pediátricos, sarcomas de tejidos blandos, oncología en adolescentes y adultos jóvenes, impresión 3D, implantes y diseños personalizados para cada paciente, salvamento y reconstrucción de extremidades, alargamiento de extremidades, transporte óseo, exosomas y oncología de precisión. El Dr. Utset se ha unido a la comunidad de MiB y espera seguir apoyando los esfuerzos para ayudar a las familias que enfrentan el osteosarcoma. Vive en Miami con su esposa, la pediatra Leah Utset, y sus dos hijos.
Despite decades of research, treatment for osteosarcoma has remained largely unchanged, especially for patients whose cancer spreads or returns. However, a growing body of evidence, summarized in the review “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types,” published in Oncotarget, highlights the gene regulator SETDB1 as a potential key player in cancer progression, immune system evasion, and resistance to therapy. Targeting this protein may offer a new direction for developing more effective treatments. Understanding Osteosarcoma Osteosarcoma is a rare but aggressive bone cancer that primarily affects teenagers and young adults. While current treatments like surgery and chemotherapy can help some patients, outcomes are much worse for those with relapsed or advanced disease. One of the reasons osteosarcomas are so difficult to treat is their complex and unstable genetics. Unlike cancers with well-defined mutations, osteosarcomas involve chaotic DNA rearrangements, making it difficult to identify precise drug targets. Adding to the challenge, the immune system often fails to recognize these cancer cells, limiting the success of immunotherapy. Full blog - https://www.oncotarget.org/2025/04/09/targeting-setdb1-a-new-strategy-for-treating-osteosarcoma/ Paper DOI - https://doi.org/10.18632/oncotarget.28688 Correspondence to - Antonin Marchais - antonin.marchais@gustaveroussy.fr, and Maria Eugenia Marques Da Costa - jenny.marquescosta@gustaveroussy.fr Video short - https://www.youtube.com/watch?v=f9WgaDoEubs Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28688 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, SETDB1, cancer epigenetics, tumor immunogenicity, mesenchymal differentiation in osteosarcoma About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Betsy Young, a physician-scientist from UCSF provides an overview of her funded work: Tumor cGAS-STING repression drives immune evasion in osteosarcoma and is therapeutically targetable via host STING activation. This work was funded by an MIB Agents 2024 OutSmarting Osteosarcoma YI Hope grant Because of Charlotte.Osteosarcoma (OS) has an immunosuppressive macrophage-rich, T-cell-depleted tumor microenvironment (TME). By performing bulk RNA seq of OS cell lines treated with STING agonist, the lab has defined an OS-specific STING activation signature, which demonstrated a significant protective effect on survival in OS patient samples. In immunocompetent OS models, systemic STING agonism shows curative anti-tumor effects, shifts the tumor microenvironment towards a pro-inflammatory phenotype, and induces immunologic memory. Importantly, host STING activation is sufficient to promote this anti-tumor immunity. The lab has demonstrated that STING activation has anti-tumor benefit in animal models and a protective effect in the human disease, nominating this innate immune sensing pathway as an important therapeutic target in OS.As a physician-scientist and a pediatric oncologist, Dr. Young's aim is to advance the field of pediatric oncology in her research career focused on the immunobiology of osteosarcoma. She completed her Pediatric Hematology/Oncology fellowship training at UCSF, receiving strong clinical training in high-risk pediatric solid tumors and early-phase clinical trials. Now, as a faculty member, she is investigating the pathogenesis of osteosarcoma metastasis in the Sweet-Cordero lab at UCSF, with a specific focus on immuno-oncology translational therapeutics.
In this episode of the Veterinary Cancer Pioneers Podcast, host Dr. Rachel Venable welcomes Dr. Duncan Lascelles, a distinguished professor at North Carolina State University and a leading expert in veterinary pain management and surgery. Dr. Lascelles explores the complex relationship between pain and cancer in veterinary patients, highlighting how both cancer and its treatments can cause significant discomfort—and how pain itself may even influence cancer progression. Together, they dive into findings from clinical and laboratory studies and share best practices for pain assessment and management. Dr. Lascelles also emphasizes the importance of early intervention, client education, and the profound impact of effective pain control on patient outcomes and quality of life. Tune in to gain a deeper understanding of how thoughtful pain management can shape the future of veterinary oncology.
Mitch Chepokas was a nine-year-old boy with Osteosarcoma, a gargantuan heart, and a dream to selflessly give to other families fighting their own childhood cancer battles. But Mitch knew he wouldn't be able to give for long, so he made a pinky swear promise with his dad to carry on that spirit of support long after he was gone.And that's exactly what Pinky Swear Foundation has done ever since.On this episode of The Medical Alley Podcast, we talk with Erica Campbell, Executive Director of Pinky Swear Foundation, about the organization's dedication to support and giving, her path and purpose, and how you can help.Send us a message!Follow Medical Alley on social media on LinkedIn, Facebook, X and Instagram.
Matthew Dietz, DO, MSEd joins us on OsteoBites to discuss Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: Consensus Recommendations from the Children's Oncology Group Bone Tumour Committee.To advance the care and cure for patients with osteosarcoma and Ewing sarcoma it is necessary to safely improve the amount and usability of diagnostic biopsy material obtained. Indeed, it is anticipated that future osteosarcoma and Ewing sarcoma clinical trials will incorporate molecular biomarkers into treatment risk stratification underscoring the need for optimal tissue collection and processing practices.Historically open/incisional biopsies were the predominant biopsy approach; however, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and reduce recovery times but have potential limitations. Including the potential for lower tissue volumes, which can limit components of clinical care - including pathologic assessment, diagnostic accuracy, and molecular evaluations - along with the opportunity for research studies with leftover tissue (following informed consent). Additionally, once biopsy material is obtained the handling of the specimen for histologic and subsequent molecular testing requires careful timing, processing and tissue prioritization to ensure all clinical and research opportunities are preserved for the patient.To help optimize these critical elements in patient care the Children's Oncology Group convened a multidisciplinary group of clinical and scientific experts to create reference recommendations for harmonizing tissue acquisition and processing algorithms for osteosarcoma and Ewing sarcoma specimens.
Michael Lizardo, MS, PhD, a staff scientist in the Poul Sorensen laboratory at BC Cancer Agency, joins us on OsteoBites to discuss how the pharmacologic inhibition of EIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis.Dr. Lizardo shares his lab's recent findings in Clinical Cancer Research on how targeting the dysregulated mRNA translation factor eukaryotic initiation factor 4A (EIF4A), via pharmacological inhibitors, prevents the protein synthesis of nuclear factor erythroid 2–related factor 2 (NRF2), which is a cytoprotective protein metastatic OS cells require to successfully colonize the harsh microenvironment of the lung. He also discusses how the EIF4A1 inhibitor, CR-1-31B, and a related clinical-grade compound (Zotatifin) prevent OS cell adaptation to oxidative stress (a major stressor in the lung) in 2D and 3D cell culture models, as well as ex vivo lung organotypic cultures. Moreover, he discusses how drug treatment can inhibit lung metastasis and prolong the survival of animal subjects in pre-clinical mouse models of metastatic OS.
It has been 6 1/2 years since Gwen Garro's son Guy was diagnosed with Osteosarcoma when he was in kindergarten in 2018. Guy has gone through many difficult surgeries and procedures since his diagnosis and has been able to lead quite an amazing life as he is now a 12 year old 6th grader. A very talented musician with a love for the theatre led him to being able to perform a song by Elton John entitled "I'm Still Standing" in front of 3000 people at Radio City Music Hall and Guy repeated that performance on January 30th of this year at the New York Rangers Casino Night Fundraiser.
In this episode of the Scope of Things, host Deborah Borfitz provides the latest on new criteria for defining and diagnosing obesity, the case for including pregnant women in vaccine trials, the subtyping of osteosarcoma, an inert gas being tested as an Alzheimer's treatment, and more. Joining the conversation is David Sall, president and CEO of Patient Enrollment Advisors, who talks about the origins of the Participant Engagement Award at SCOPE 2025 and how the conversation around participant engagement has changed over time (and the changes that still need to happen). Finally, we have Allison Proffitt, editorial director of Clinical Research News, interviewing Trân Lê and Sohit Gatiganti, co-founders of Grove AI and the winners of the Participant Engagement Award at SCOPE 2025. The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.
Alice Soragni, PhD shares information about PREMOST: an organoid-based functional PREcision Medicine trial in OSTeosarcoma (NCT06064682), a clinical trial that is studying the feasibility of using organoids for predicting drug response and guiding therapy in osteosarcoma.Patient-derived tumor organoids (PDTOs) are lab-grown replicas of tumors that closely resemble the original cancer in both structure and behavior. These models can be rapidly created from small samples obtained during biopsies or surgeries, allowing us to test their responses to different drugs in the lab. This makes them highly valuable for developing personalized treatment strategies, particularly in light of a growing body of evidence showing how PDTOs can in many cases accurately mimic clinical responses. The Soragni Lab has developed a unique platform to grow these organoids efficiently from osteosarcoma surgical samples. They can create these three-dimensional avatars without needing complicated cell sorting or lengthy lab procedures. This means they can start testing drugs and get results within a week of the surgery, a turnaround that is rapid enough to potentially be used in the future to help guide treatment decisions In a pilot study, they found that testing drugs on these organoids provided insights that closely matched the patients' actual clinical outcomes. Osteosarcoma organoids with low viability after neoadjuvant chemotherapy matched patients who experienced higher tumor cell death (necrosis) after treatment and long-term disease status. The lab also investigated responses of PDTOs from advanced, recurrent, and metastatic sarcomas and found that the viability of these organoids in the lab correlated with the time to the next treatment in patients. The data suggests that osteosarcoma organoids could help predict how well some treatments may work. Encouraged by these promising results, the Soragni Lab has initiated a clinical trial to further explore the use of PDTOs to predict osteosarcoma therapy responses. Dr. Soragni will describe the study design for this first-of-its-kind, organoid-based clinical trial in sarcoma.Alice Soragni, PhD, is an Associate Professor in the David Geffen School of Medicine at UCLA, and a member of the Jonsson Comprehensive Cancer Center. She has a Bachelor and Master of Science cum Laude from the University of Bologna, Italy, and a PhD from the ETH of Zuerich, Switzerland. Her laboratory couples basic research into mechanisms of disease to the development of novel therapeutic strategies. Her expertise lies in the development of tumor organoid models to investigate the biology of rare tumors such as osteosarcoma and perform screenings for functional precision medicine applications.
In the latest episode ofosTEAo: Spilling the Tea on Osteosarcoma and AYA Cancer, young adult osteosarcoma survivors Mia, Sammy, Sloan, and Mackenzie share how their pets became their greatest sources of comfort, laughter, and unwavering support during treatment and recovery.From Sloan's dog Sam instinctively wrapping around their leg post-surgery to Mackenzie's pup carefully avoiding pressure on her biopsy site, these furry friends always seemed to know when their humans needed extra love. Mia recalls how her cat Enzo made a dramatic mess the moment she returned from the hospital—because, of course, he needed to remind her who was boss! And Sammy's pet was her rock through every twist and turn, proving that while so much changes during cancer treatment, the love of a pet remains constant.Tune in for heartfelt stories, funny pet antics, and a celebration of the incredible healing power of animals. Because sometimes, the best medicine has four legs and a wagging tail.
El Dr. Jorge Alegría Baños, oncólogo médico de Médica Sur en la Ciudad de México, nos habla durante el 7º Taller RISE 2025: Residents In Search of Excellence del Colegio Mexicano de Oncología Médica, sobre sarcomas óseos: osteosarcoma y sarcoma de Ewing.La realización integral de este evento fue gracias a: AstraZeneca México y Pfizer México.Fecha de grabación: 31 de enero de 2025. Todos los comentarios emitidos por los participantes son a título personal y no reflejan la opinión de ScienceLink u otros. Se deberá revisar las indicaciones aprobadas en el país para cada uno de los tratamientos y medicamentos comentados. Las opiniones vertidas en este programa son responsabilidad de los participantes o entrevistados, ScienceLink las ha incluido con fines educativos. Este material está dirigido a profesionales de la salud exclusivamente.
BUFFALO, NY – February 14, 2025 – A new #review was #published in Oncotarget, Volume 16, on February 12, 2025, titled “SETDB1 amplification in osteosarcomas: Insights from its role in healthy tissues and other cancer types.” Authors Elodie Verdier, Nathalie Gaspar, Maria Eugenia Marques Da Costa, and Antonin Marchais from the Gustave Roussy Cancer Campus analyzed recent studies on a gene called SETDB1, which may play a key role in osteosarcoma, a type of bone cancer that mostly affects teenagers and young adults. Their review highlights how SETDB1 helps cancer cells grow, resist treatment, and avoid the immune system. Because of this, blocking SETDB1 could be a promising new way to treat osteosarcoma. Osteosarcoma is a fast-growing bone cancer that is usually treated with surgery and chemotherapy. However, if the cancer spreads or returns, treatment options are very limited. Scientists are searching for new ways to stop this disease, and recent studies have found that osteosarcoma cells often have extra copies of the SETDB1 gene. This seems to make the cancer more aggressive and harder to treat. “Whole exome sequencing of osteosarcoma samples from both diagnosis and relapses has highlighted several factors, including SETDB1, that are amplified in the most aggressive forms of the disease.” SETDB1 is involved in epigenetics, meaning it affects how genes are turned on and off without changing the DNA itself. The review explains that SETDB1 helps tumors hide from the immune system, making it difficult for the body to fight the cancer naturally. The researchers believe that blocking SETDB1 could help the immune system recognize and attack osteosarcoma cells. Some experimental drugs that target SETDB1 are already being tested in the lab. The review also describes how SETDB1 influences key cancer pathways, such as Wnt signaling, which helps cancer cells grow, and epithelial-mesenchymal transition (EMT), a process that allows cancer to spread. The authors suggest that combining SETDB1-blocking drugs with immunotherapy or radiation could be an effective new strategy for treating osteosarcoma. Another key finding is that SETDB1 may help cancer cells become resistant to chemotherapy, making treatment less effective. This means that drugs targeting SETDB1 could not only slow cancer growth but also make existing treatments work better. While more research is needed, this review brings attention to SETDB1 as a potential treatment target. Scientists hope that a deeper understanding of SETDB1 will lead to new therapies that improve survival rates for osteosarcoma patients. DOI - https://doi.org/10.18632/oncotarget.28688 Correspondence to - Antonin Marchais - antonin.marchais@gustaveroussy.fr, and Maria Eugenia Marques Da Costa - jenny.marquescosta@gustaveroussy.fr Video short - https://www.youtube.com/watch?v=f9WgaDoEubs About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Científicos españoles logran un avance fundamental para frenar el osteosarcoma, un cáncer de hueso complejo que afecta a jóvenes de entre 10 y 20 años. Isidro Cortes-Ciriano, investigador principal en Instituto Europeo de Bioinformática en Cambridge y coautor principal del estudio, ha explicado en el informativo 24 horas de RNE que han mirado "el genoma de casi 400 osteosarcomas y hemos descubierto el mecanismo molecular que explica el origen de la mitad de tumores en niños y en adultos". Estos datos lo que indican es "cómo no atajar ese tumor", es decir, "nos fuerza a enfocar cómo tratarlo de forma diferente", ha explicado. Y bajo su opinión, sería con inmunoterapia.Escuchar audio
After hearing something pop in her left shoulder during a virtual school physical education class during the pandemic, 12 year old Grace Messinger was diagnosed with Osteosarcoma. Grace went through some very difficult treatment including 2 Thoracic Surgeries which removed a total of 55 nodules from her lung with many of them being cancerous, a Limb Salvage surgery, and never had any type of break from this very difficult bone cancer. Despite having a great attitude and fighting hard, Grace passed away on September 27th of 2023, just after her 15th birthday.
Welcome to Season 2 of the Orthobullets Podcast. Today's show is Core, where we review Core Knowledge for Orthopaedic Surgeons. This episode will cover the topic of Conventional Intramedullary Osteosarcoma, from our Pathology section at Orthobullets.com. Follow Orthobullets on Social Media: Facebook Instagram Twitter LinkedIn YouTube
Osteosarcoma Webinar Series: Chelsey Burke, MD, a physician-scientist from Memorial Sloan Kettering Cancer Center and an OutSmarting Osteosarcoma Young Investigator 2024 grant recipient, shares findings from her work studying the evolution of osteosarcoma tumors. At present, we have a limited understanding of how osteosarcoma tumors change with conventional treatment and go on to develop drug resistance. Dr. Burke discusses the use of mouse models to investigate osteosarcoma tumor evolution and identify emerging resistance mechanisms that can be therapeutically targeted.Chelsey Burke, MD is an assistant attending and young investigator at Memorial Sloan Kettering Cancer Center. After graduating from the University of Iowa with a B.S. in biology, Dr. Burke obtained her medical degree from St. George's University School of Medicine. Following pediatric residency at Advocate Children's Hospital in Chicago, where she served as pediatric chief resident, she joined the combined Memorial Sloan Kettering and New York Presbyterian-Weill Cornell pediatric hematology and oncology fellowship program. During fellowship, Dr. Burke joined the laboratory of Dr. Filemon Dela Cruz and Dr. Andrew Kung where her research focuses on pediatric cancer modeling and preclinical drug development. Dr. Burke has a particular interest in bone sarcomas, including osteosarcoma, and is involved in the preclinical evaluation of several novel therapeutics. She hopes this work can be translated into early phase clinical trials and, ultimately, improve outcomes for children, adolescents, and young adults with high-risk sarcomas.
One of our MIB Agents OutSmarting Osteosarcoma 2024 grant recipients, Dr. Chris Richards, an Associate Professor from the University of Kentucky provides an overview of his funded work on macrophage engineered vesicles to treat pediatric osteosarcoma. This presentation focuses on the development of nanoscale vesicles derived from immune cells that can be utilized as immunomodulatory and therapeutic delivery platforms. Dr. Richards is a Professor in the Department of Chemistry at the University of Kentucky where he also serves as the Director of the Light Microscopy Facility and the Director of the Bioelectronics and Nanomedicine Center. His lab has developed novel nanoscale biomaterials for therapeutic delivery and in vivo sensing within the central nervous system. Incorporating these materials with nanofabricated devices has enabled his lab to develop new platforms for interrogating biological systems in cell culture, isolated tissue, and in vivo. Research in the Richards lab also focuses on the development of ensemble and single-molecule fluorescence spectroscopy techniques for the study of complex biological systems. His lab has recently applied this approach to study substance use disorders along with the development of therapeutic delivery platforms for cancer and spinal cord injury. Dr. Richards received his bachelor's degree in chemistry from the University of Maine and his PhD in physical chemistry from the Georgia Institute of Technology. He was also a postdoctoral researcher at Caltech where he was also a Beckman postdoctoral Scholar.
In episode 82 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Tony Trent, President of the Tyler Trent Foundation. Tune in as Tony shares his son's osteosarcoma diagnosis and his passion for better outcomes through pediatric cancer research. For more on Tyler's story, purchase his book at tylertrentbook.com.
One of our MIB Agents OutSmarting Osteosarcoma Young Investigator 2024 grant recipients, Arianexys Aquino-López, MD, PhD, a physician-scientist from Texas Children's Hospital/Baylor College of Medicine will provide an overview of her funded work on Repurposing Virus Specific T cells as Immune Therapy for Osteosarcoma. In this presentation, she discusses repurposing virus-specific T cells so that they become an immune therapy for osteosarcoma. She will also describe how oncolytic virotherapy promotes immune stimulation at the tumor site increasing the anti-tumor activity of virus-specific T cells.Dr. Arianexys Aquino-López is an Instructor at the Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine. Dr. Aquino-Lopez is committed to a career as a pediatrician-scientist with a particular interest in improving treatment options for children with cancer through the design of novel immune therapies, including cell therapies and antibody therapies. She is also interested in studying the impact of tumor microenvironment in immune suppression to develop approaches to overcome cancer immune evasion. Witnessing her brother go through pediatric cancer treatment served as an inspiration for her to study ways to improve cancer therapies.
Osteosarcoma Webinar Series: Osteosarcoma Webinar Series: One of our MIB Agents OutSmarting Osteosarcoma 2024 grant recipients, Dr. Shahana Mahajan, a Professor and Principal Investigator from Hunter College of the City University of New York will provide an overview of her funded work on repurposing drugs for metastatic osteosarcoma. Dr. Mahajan will share the recent findings from her lab on testing the efficacy of Riluzole in osteosarcoma cell lines and patient-derived cell lines. Riluzole is a glutamate-release inhibitor and has been used for Amyotrophic Lateral Sclerosis (ALS) for decades and is being tested for other neurodegenerative disorders. Riluzole has shown promising results in glutamate receptor-expressing melanoma and other cancer types. The Mahajan Lab efforts are invested in establishing Riluzole as a possible treatment option for osteosarcoma for which targeted therapy has not been successful due to lack of oncogenic driver mutations. In their lab, Riluzole has shown efficacy in inhibiting proliferation, migration, and invasive ability of osteosarcoma cells in 11 cell lines and 4 patient-derived lines. Dr. Mahajan earned a Ph.D. from the Indian Institute of Science, a premier Institute in India in the field of Molecular Biology. She did postdoctoral studies at Weill Cornell Medical College in the Department of Pharmacology and at NYU Langone Medical Center in the Department of Biochemistry. She continued her research at NYU Langone Medical Center as a Research Assistant Professor until she joined Hunter College as an Assistant Professor in 2007. At Hunter, she continued her research neuroscience to investigate glutamate-induced excitotoxicity in rat hippocampal neurons. After her lab was lost to Hurricane Sandy, she reinitiated her research in osteosarcoma. In 2015, her lab moved to Belfer Research Building which is a part of Weill Cornell Medical College. She was appointed as an adjunct faculty at Weill Cornell Medical College. After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.
Joanne Tuohy, DVM, PhD from Virginia Tech and the Virgina-Maryland College of Veterinary Medicine will be sharing information about canine trials studying histotripsy as a novel tumor ablation modality for treating osteosarcoma. Histotripsy is a focused ultrasound tumor ablation technique that is non-invasive, non-ionizing and non-thermal, and it also has potential to induce immunomodulatory effects after tumor ablation. Histotripsy is capable of delivering highly precise tumor ablation and spares normal tissues adjacent to the ablation site. Histotripsy has exciting potential to serve as a non-surgical limb salvage treatment for osteosarcoma. Additionally, due to its immunomodulatory effects, histotripsy has potential to be synergistic with immunotherapies and increase the efficacy of immunotherapies in osteosarcoma. After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.
Welcome to the Orthobullets Podcasts. Today's show is Total Recall, where we review all of the highest yield points for anyone studying for the Orthopedic in Training Exam or part one of the ABOS Board Exam. Today's episode will cover the topic of Conventional Intramedullary Osteosarcoma from the Pathology section at Orthobullets.com. Follow Orthobullets on Social Media: Facebook Instagram Twitter LinkedIn YouTube
On Ep. 98 of the WAO Podcast pres. by Harrod Outdoors and Mack's Lure, our guest is Dylan Smith, a 15year-old outdoorsmen that is fighting Osteosarcoma. His attitude and outdoor exploits are an inspiration to Bobby and Richy. - WAO on Instagram Powered by HarrodOutdoors.com and MacksLure.com. If you have questions or would like us to discuss a certain topic, please send us a message on one of our social media platforms or send an email to info@harrodoutdoors.com.
Paul Romness, CEO of OS Therapies (OSTX), joins Nicole Petallides at the NYSE after the company recently completed a critical phase of its Osteosarcoma research. As OS Therapies readies to send its data to the FDA, Paul discusses the similarities of the disease between humans and dogs and looks ahead to researching other solid tumors. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185 Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7 Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore Watch on DistroTV - https://www.distro.tv/live/schwab-network/ Follow us on X – https://twitter.com/schwabnetwork Follow us on Facebook – https://www.facebook.com/schwabnetwork Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about
Welcome to Season 2 of the Orthobullets Podcast. Today's show is Foundations, where we review foundational knowledge for frontline MSK providers such as junior orthopaedic residents, ER physicians, and primary care providers. This episode will cover the topic of Conventional Intramedullary Osteosarcoma, from our Pathology section at Orthobullets.com. Follow Orthobullets on Social Media: Facebook Instagram Twitter LinkedIn YouTube
Dr. Troy McEachron joined us on OsteoBites to discuss the molecular and cellular deconstruction of metastatic osteosarcoma. Immunotherapy holds great promise for a subset of patients whose tumors respond to this innovative and remarkable approach. The therapeutic benefit for patients with osteosarcoma has been largely underwhelming, prompting clinical, translational, and basic scientists to ask why. Dr. McEachron's laboratory is focused on understanding the oncogenic and immunoregulatory mechanisms within the metastatic osteosarcoma microenvironment and how they impact therapeutic efficacy. He discusses his lab's current work in using various -omic technologies to deconstruct metastatic osteosarcoma.Dr. McEachron earned his doctorate in Molecular and Cellular Pathology from the University of North Carolina at Chapel Hill in 2011. He completed postdoctoral fellowships at St. Jude Children's Research Hospital and at the Translational Genomics Research Institute. In 2016, Dr. McEachron joined the faculty of the Keck School of Medicine at the University of Southern California as an Assistant Professor in the Department of Translational Genomics (primary appointment) and the Department of Pediatrics (secondary appointment). Dr. McEachron joined the Pediatric Oncology Branch of the National Cancer Institute in 2021 where he leads the Integrated Solid Tumor Biology Section. The major focus of his laboratory is to molecularly dissect the microenvironment of pediatric metastatic osteosarcoma to better understand the biology of metastatic disease and identify therapeutically actionable targets.
Nine year old Luka joins Matt and Mel in the studio this episode, after writing a lovely feedback email about his most favourite animal - greyhounds! Walter, Poppy, Huey and Alfie are all lucky rescues that have known the love of Luka and his family (including Grandma!) Luka's endearing affection for greyhounds, plus his cheeky giggle and mature insight into the complexities of fostering and adoption will melt your heart... This podcast finishes with a touching tribute from Mel to her Heart Dog, the beautiful Anna, who was taken suddenly and too soon, just days before recording. Please click the link to learn more about Osteosarcoma in Greyhounds and fill in the survey to help Free The Hounds track the data of this dreaded genetic disease, and hopefully find a way to eradicate it from our beloved breed. https://www.freethehounds.com.au/dr-belinda-oppenheimer-examines-osteosarcoma-in-greyhounds/ https://www.freethehounds.com.au/survey/
Brigitte Brisson, DMV, DVSc, DACVS from the Ontario Veterinary College at the University of Guelph joined us on OsteoBites to introduce Magnetic Resonance guided High Intensity Focused Ultrasound as a treatment modality for osteosarcoma and describe preliminary results in canine patients.High Intensity focused ultrasound (HIFU) is a non-invasive percutaneous thermal ablation technique that allows deep tissue treatment with precise control over the shape and location of energy deposition. It causes minimal collateral damage and can be used to treat primary and metastatic tumours. In addition to its role in tumour ablation, HIFU has attracted attention for its potential to stimulate the immune system and possibly mount a response against metastasis. In humans, HIFU has been used for ablation of a variety of soft tissue tumours and most recently, it has been used in bone applications, specifically for the treatment of osteoid osteoma (OO) lesions in pediatric patients. Other reported bone applications include bone metastasis and osteosarcoma.Dr. Brigitte Brisson is a professor of soft tissue surgery in the Department of Clinical Studies at the Ontario Veterinary College (OVC). She graduated from the Faculté de Médecine Vétérinaire at the University of Montreal in 1996. She performed a small animal rotating internship at the OVC followed by a Surgery residency with concurrent Doctor of Veterinary Science (DVSc) in small animal surgery. She became board certified in small animal surgery (ACVS) in 2001 and has since been on faculty at the Ontario Veterinary College. She is an ACVS Founding Fellow in Minimally Invasive Surgery and a Founding Member of Veterinary Neurosurgical Society.
Mecklin Ragan is currently a General Surgery Resident in Fairfax , Virginia who hopes to become a Pediatric Oncology surgeon . She was also the older sister by 18 months of her brother James who was diagnosed with Osteosarcoma in 2006 at the age of 13. Mecklin tells the story of James who went through a 7 1/2 year protocol which unfortunately ended with his passing from Rice University during his sophomore year. Mecklin is the co-founder of the Triumph Over Kids Cancer Foundation, which is doing a great deal of work to help Pediatric Cancer patients and their families.
Diana Azzam, PhD joined us on OsteoBites to discuss her lab's work on functional precision medicine for the treatment of pediatric and adult cancers. This presentation describes the foundational principles of functional precision medicine as applied to pediatric cancers and how major technological improvements as well as an explosive broadening of the cancer pharmacopeia has enabled the bridging of genomics with functional drug testing as clinical decision support tools to impact patient care.Diana Azzam, PhD, is an Assistant Professor and Research Director of the Center for Advancing Personalized Cancer Treatments at Florida International University. She has a Masters in Biochemistry from the American University of Beirut, Lebanon and a PhD in Biochemistry & Molecular Biology from the University of Miami, Florida. Her lab focuses on implementing functional precision medicine (FPM) approaches in adult and pediatric cancer patients that have run out of treatment options. Working with local hospitals including Nicklaus Children's Hospital and Cleveland Clinic Florida, her lab delivers individualized treatment plans based on a patient's cancer genomic profile and ex vivo drug response. She is currently engaged in two clinical studies to assess feasibility and clinical utility of FPM in relapsed/refractory patients with childhood cancer (ClinicalTrials.gov registration: NCT05857969) and adult cancer (ClinicalTrials.gov registration: NCT06024603). Dr. Azzam is working on setting up the first CLIA-certified lab in the State of Florida dedicated for functional cancer drug testing. Her goal is to launch large-scale prospective multi-center randomized clinical trials to better assess efficacy of FPM approaches in the treatment of refractory/relapsed cancers. In parallel, she is working on utilizing FPM as a tool to reduce health disparities in childhood cancer patients from minority populations. She is also integrating a novel machine learning approach to identify specific biomarkers among minority populations that can be targeted using FDA-approved drugs. Her lab also investigates cancer stem cells and how they may result from chronic environmental exposures to toxic metals such as arsenic.After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.
In today's podcast, we have the pleasure of speaking with Angie Giallourakis, a dedicated advocate and founder of the Steven G. Cancer Foundation and Elephants and Tea. Angie shares her powerful story of being a caregiver to her son Steven, who battled cancer twice. Steven was first diagnosed with stage four osteosarcoma in 2006, and later with secondary acute myelogenous leukemia (AML) in 2008, necessitating a bone marrow transplant.Angie recounts the emotional and physical toll of Steven's journey, describing the intense periods of treatment and the unexpected challenges they faced. After his bone marrow transplant, Steven experienced graft-versus-host disease (GVHD). Angie shares vivid anecdotes, including a harrowing moment when Steven's salivary glands swelled, causing his face to balloon. This incident, among others, highlights the unpredictable nature of GVHD and the constant vigilance required from caregivers.Angie emphasizes the importance of stress management for caregivers. She advocates for finding personal ways to cope, whether through exercise, yoga, meditation, or prayer. Her own methods include Yoga Nidra, a type of meditation, and seeking solace in prayer. She also stresses the importance of good nutrition and staying hydrated, which can be challenging during long hospital stays.Drawing from her experiences, Angie advises caregivers to seek help when needed and to communicate openly with their loved ones and medical teams. She underscores the necessity of validating the patient's pain and symptoms, as Steven's experience with inflammation throughout his body was initially dismissed by some as psychological.The conversation shifts to Angie's founding of the Steven G. Cancer Foundation. Motivated by the outdated treatments Steven received, she aimed to raise awareness and fund research for adolescent and young adult (AYA) cancer. She also talks about Elephants and Tea, a magazine by and for cancer patients, founded with her son Nick. The magazine provides a platform for unfiltered stories from cancer patients and has expanded to include workshops, community support, and therapeutic resources.Angie's message to new caregivers is clear: understand the potential challenges, communicate effectively, and don't hesitate to ask for and accept help. She highlights the importance of social support, both for patients and caregivers, to navigate the emotional and physical demands of cancer treatment.As we wrap up, Angie encourages listeners to reach out to organizations, consume available resources, and connect with others in similar situations. Her final words resonate with a message of hope and validation: you are not alone in this journey.More:Steven G. Cancer Foundation: https://www.stevengcancerfoundation.orgElephants and Tea: https://www.elephantsandtea.comNational Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.This season is made possible thanks to donations from Syndax and Incyte.https://syndax.com/https://incyte.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/
After seeing her then 9 year old son Jaxen hopping on one leg in June of 2023 because he felt pain, Maggie Licea wanted to take Jaxen to his pediatrician who was not available. Instead, Maggie took Jaxen to the nurse practitioner and told her that she suspected that he had cancer. The nurse practitioner disagreed but Maggie's persistence finally prevailed and Jaxen was given the necessary testing that revealed a diagnosis of Osteosarcoma. Jaxen is nearly 14 months past his original diagnosis and unfortunately suffered a relapse from this form of Bone Cancer last week.
Tune in to help us celebrate 4 years since his last chemo session. Host Vincent A. Lanci met today's guest through Tampa General Hospital. They take annual trips to the State Capitol yearly to share their stories. Today, you learn his. Welcome, Sean Barnette. He shares: His battle with cancer, throughout treatment and post-treatment. How that has affected not only physical health but also mental health, especially post-treatment. How being a young man has affected his journey in destigmatizing mental health. Welcome back to A Mental Health Break! If you enjoy the show, please subscribe for weekly episodes and rate the show 5 stars to help others join our conversations!Sean Barnette (b. 2003) is an undergraduate at Florida State University studying Choral Music Education. In January 2020, Sean was diagnosed with osteosarcoma, a rare form of bone cancer in his left tibia and fibula, at age 16. Sean underwent nine months of intense chemotherapy and a limb salvage surgery in April 2020, where 13 centimeters of bone was removed and replaced with an endoprosthesis. He has been involved with the Junior Advisory Board of the MIB Agents, the leading pediatric osteosarcoma research and nonprofit organization, a member of the Patient and Family Advisory Council at Tampa General Hospital, and the founder of the Harmonies for Health project, a series of charity concert to raise money for the Children Cancer Center in Tampa. Inspired by his battle with cancer, Sean believes in the transformative nature of music and hopes to inspire audiences through his composition and inspire his students as an educator. Some additional areas of discussion:Making time for yourselfSelf-care checks throughout the day Planning, without planningBenefits of being in a communityKnowing he's making a differenceFavorite parts of We Are TGH Day in Tallahassee We would love to stay connected. You can subscribe for more shows on all podcast platforms and join our vibrant community on social media! For more about our show and our esteemed guests, visit www.vincentalanci.com. Question for the host of guest? Email Danica at PodcastsByLanci@Gmail.com. We can't wait to connect with you!Episode Music Credits: Adventure by MusicbyAden | https://soundcloud.com/musicbyadenCRISIS LINE: DIAL 988Have a question for the host or guest? Are you looking to become a show partner? Email Danica at PodcastsByLanci@gmail.com to get connected.
José Granados Soler, DVM, MSc, PhD and Rachel Allavena, PhD from the University of Queensland School of Veterinary Science join us on OsteoBites to discuss exploring novel immunotherapies for canine osteosarcoma. During this presentation, they delve into a pioneering clinical trial for canine osteosarcoma, share cutting-edge insights and explore how novel immunotherapies could revolutionize treatment outcomes for our furry companions. Dr. José Granados Soler, DVM, MSc, PhD serves as a small animal surgeon, educator, and researcher at The University of Queensland in Australia, collaborating with Prof. Allavena on pioneering immunotherapeutic trials for osteosarcoma and other cancers in dogs. He remains dedicated to making impactful contributions to the field, with a steadfast commitment to continuous learning and improvement.Professor Rachel Allavena is the Deputy Head of the School of Veterinary Science at The University of Queensland. She teaches toxicology, pathology, animal welfare, and laboratory animal science to science and veterinary students. Professor Allavena is a specialist veterinary anatomic pathologist and her canine trials have focused on bone cancer, melanoma, lymphoma and mastocytoma.
Send us a Text Message.Your daughter has cancer. Can there be four words more frightening for a parent to hear? Our guest today is Colleen Cappiello, a Pilates studio owner who has found herself juggling the running of her studio and being her daughter's fiercest advocate as her daughter recovers from cancer. When we have outside challenges that impact our ability to run our studios, where or who do we turn to? I'll be discussing this question with Colleen as well as how this event has impacted her Pilates businessAbout Darien Gold ~ https://www.dariengold.com Instagram: https://www.instagram.com/darien_gold_pilates_expert Facebook: https://www.facebook.com/dariengold Music credits ~ Instagram: @theotherjohnmayer Email: mayerranchrecordings@gmail.comTo contact Colleen Cappiello ~ colleen.cappiello@clubpilates.com, https://www.clubpilates.com/pompanobeachSupport the Show.
In the realm of health and wellness, the quest for effective strategies often leads individuals down various paths, each marked by its own set of challenges and triumphs. Among these journeys, the story of Jon Hegarty and his brother Christian stands out as a beacon of hope and resilience in the face of adversity. Through their exploration of integrative healing modalities, they uncovered a wealth of knowledge and experiences that reshaped their approach to combating cancer.Join me today, as Jon shares the trials and tribulations, as well as as the wins and successes he and his brother experienced together as they battled Christian's osteosarcoma diagnosis. Today, things are GOING WELL and Jon is determined to continue that trend.Learn more about Jon Hegarty at Going Well:https://goingwell.org/Suggested Resource Links:LINK: NorthStar Grounding ProductsINSTAGRAM: NorthStar GroundingPODCAST: Believe Big and Dr. Leigh Erin ConnealyBOOK: Radical Remission by Dr. Kelly TurnerLINK: PubMed article regarding Osteosarcoma and MistletoeYour donations power our podcast's mission to support cancer patients with hope, insights, and resources. Every contribution fuels our ability to uplift and empower. Join us in making a lasting impact. Donate now!
In this episode, we review the high-yield topic of Intramedullary Osteosarcoma from the Pathology section. Follow Orthobullets on Social Media: Facebook Instagram Twitter LinkedIn YouTube --- Send in a voice message: https://podcasters.spotify.com/pod/show/orthobullets/message
156: Hammer Down Cancer - Hope on the Horizon Purdue University is hammering down on cancer with research, fundraising and real people making a difference in pursuit of a cure. Hope is alive. Andy Mesecar; Tony and Kelly Trent Today's Lexi: Ελπίδα - Elpida - Hope In Today's Episode: A trip to sunny Naples, Florida for Purdue University President's Council Back-to-Class weekend proves to informative, enlightening and a ray of hope for those struggling with cancer. Kiki shares her candid and heartfelt conversation with Dr Andrew Mesecar Department Head, Department of Biochemistry Director, Purdue Center for Cancer Research and Kelly and Tony Trent parents of Tyler Trent. Tyler Trent, in case you do not know the name, is the former Purdue student who inspired countless sports fans with his gratitude and grace. He passed away from a rare form of bone cancer in 2019 at the age of 20 years old. According to ESPN Trent first earned the admiration of the Boilermakers football team by camping outside the stadium in September 2017 prior to the team's Big Ten home opener against No. 8 Michigan. He posed for a picture with head coach Jeff Brohm the morning of the game. Trent did not initially tell Brohm that he had spent the previous afternoon at a chemotherapy session to treat Osteosarcoma. This fortuitous encounter propelled a new trajectory of scientific research for peds cancer at Purdue. Learn all about the giant leaps being taken in pursuit of targeting chemo and finding a cure. Plus, two parents, Tyler's mother and father, who now dedicate their life to cancer awareness, education, fundraising and outreach. This episode is not to be missed as we can each make a difference in our health and wellness when we look for viable solutions to change for the better. Today's Ola Kala Moment: Love Notes Resources: Purdue Cancer Institute ESPN Tyler Trent Purdue For Life GIANT LEAPS Mesecar Lab The Upset Tyler Trent Foundation Credits: Music: Spiro Dussias Vocals: Zabrina Hay Graphic Designer: Susan Jackson O'Leary
© 2020-2025 Ivy Podcast Discovery LLC
